Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.22 --0%
EPS Growth %: +400.0%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
MSGM, SMID, VISL, More
EPS Growth %: +400.0%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.29), versus ($0.36) reported last year. Revenue for the quarter came in at $4.4 million, versus $3.5 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is Treasury selloff a major issue for stock market bulls?
- INVO Fertility (IVF) Tops Q2 EPS by 105c
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
